Sigilon Revenue and Competitors
Claim your profile
Estimated Revenue & Valuation
- Sigilon's estimated annual revenue is currently $11.4M per year.
- Sigilon's estimated revenue per employee is $142,125
- Sigilon's total funding is $263.2M.
- Sigilon's current valuation is $68.5M. (January 2022)
Employee Data
- Sigilon has 80 Employees.
- Sigilon grew their employee count by -1% last year.
Sigilon Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.8M | 73 | -39% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $3.1M | 26 | 63% | N/A | N/A |
#4 | $29.6M | 125 | 18% | $351M | N/A |
#5 | $15.8M | 84 | -18% | $312.8M | N/A |
#6 | $0.5M | 7 | 17% | N/A | N/A |
#7 | $235M | 269 | -43% | $340.9M | N/A |
#8 | $2.2M | 28 | 4% | N/A | N/A |
#9 | $0.6M | 10 | -9% | N/A | N/A |
#10 | $0.5M | 9 | 29% | N/A | N/A |
What Is Sigilon?
Harnessing the full power of cell therapeutics. Cambridge, MA
keywords:N/A
$263.2M
Total Funding
80
Number of Employees
$11.4M
Revenue (est)
-1%
Employee Growth %
$68.5M
Valuation
N/A
Accelerator
Sigilon News
2022-04-17 - Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Given Consensus ...
Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Given Consensus Rating of Buy by Brokerages. Posted by admin on Apr 22nd, 2022.
2022-03-30 - How Will the Market React to Sigilon Therapeutics Inc (SGTX) Stock Getting
a Bullish Rating
The market has been high on Sigilon Therapeutics Inc (SGTX) stock recently. SGTX gets a Bullish score from InvestorsObserver Stock Sentiment...
2022-03-22 - Sigilon Therapeutics Reports Fourth Quarter and Full Year ...
Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of chronic diseases by harnessing the power of the human...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20M | 80 | 1% | N/A |
#2 | $18.8M | 80 | -21% | $198.5M |
#3 | $12M | 80 | N/A | N/A |
#4 | $15.2M | 80 | 33% | $56M |
#5 | $15.2M | 80 | 33% | $90M |